New dual therapy aims to beat stomach bug with fewer pills

NCT ID NCT06734260

Recruiting now Disease control Sponsor: Eighth Affiliated Hospital, Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new two-drug combination (keverprazan and amoxicillin) to treat H. pylori, a stomach infection that can cause ulcers and cancer. About 477 adults will receive different doses and treatment lengths (10 or 14 days) to find the best balance of effectiveness, fewer side effects, and lower cost. The goal is to offer a simpler alternative to current four-drug regimens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI ERADICATION RATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELICOBACTER PYLORI ERADICATION RATE

Contacts and locations

Locations

Eighth Affiliated Hospital,Sun Yet-san University
RECRUITING

Shenzhen, Guangdong, 518033, China
Puning Overseas Chinese Hospital
RECRUITING

Puning, Guangdong, 515300, China
The Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510655, China
Xiangyang Hospital of Traditional Chinese Medicine
RECRUITING

Xiangyang, Hubei, 441000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.